Central Obesity, Body Mass Index, Metabolic Syndrome and Mortality in Mediterranean Breast Cancer Patients
Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Assunta Luongo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Egidio Celentano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfonso Amore(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberto Bianco(Federico II University Hospital), Piergiacomo Di Gennaro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mario Giuliano(Regione Campania), Joao Breda, Alessandra Calabrese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Porciello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sergio Coluccia(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rosa Giannatiempo, Carlo La Vecchia(University of Milan), Elvira Palumbo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Trasacco(University of Naples Federico II), Claudia Calderaio(University of Naples Federico II), Giuseppe Buono(Federico II University Hospital), Sara Vitale(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Livia Silvia Augustin(St. Michael's Hospital), Francesco Schettini(Target (United States)), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Flavia Nocerino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis
|Nature Communications|2020|694
Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC)
|Nutrition Metabolism and Cardiovascular Diseases|2015|691